Agenus Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:3em;'>AGE</div>
AGEN -- USA Stock  

USD 2.64  0.08  3.12%

While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to outline Agenus Inc. What exactly are Agenus shareholders getting in April? Is current the firm value sustainable? We will go over Agenus Inc valuation drivers to give you a better outlook on taking a position in it.
Published over a month ago
View all stories for Agenus | View All Stories
Is Agenus (NASDAQ:AGEN) valuation reliable?
The company currently holds 37.74 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies.
We provide trade advice to complement the prevailing expert consensus on Agenus Inc. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Agenus Inc using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Agenus Inc based exclusively on its fundamental and basic technical indicators. By analyzing Agenus's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Agenus's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Agenus. We calculate exposure to Agenus's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Agenus's related companies.

Agenus Inc Investment Alerts

Agenus investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Agenus Inc performance across your portfolios.Please check all investment alerts for Agenus

Agenus Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Agenus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Agenus competition to find correlations between indicators driving the intrinsic value of Agenus.

How Agenus utilizes its cash?

To perform a cash flow analysis of Agenus, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Agenus is receiving and how much cash it distributes out in a given period. The Agenus cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Agenus Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (142.76 Million)

Acquisition by Hirsch Susan B of 5092 shares of Agenus subject to Rule 16b-3

Legal trades by Agenus insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Agenus insider trading alert for grant of common stock by Hirsch Susan B, the corporate stakeholder, on 5th of April 2021. This event was filed by Agenus Inc with SEC on 2021-04-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Agenus Investor Appetite?

Agenus Inc reported the previous year's revenue of 91.41 M. Net Loss for the year was (173.57 M) with loss before overhead, payroll, taxes, and interest of (18.29 M).
 2018 2020 2021 (projected)
Receivables938.14 K14.66 M15.82 M
Inventories55.49 K49.94 K51 K

Margins Breakdown

Agenus profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Agenus itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Agenus profit margins.
Operating Margin(57.99)
EBITDA Margin(0.49)
Gross Margin1.17
Profit Margin(0.89)

Agenus Average Assets is quite stable at the moment. Agenus Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years. Furthermore, Agenus Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. Agenus Average Assets is quite stable at the moment. Agenus Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years. The latest value of Agenus Earnings Before Interest Taxes and Depreciation Amortization USD is -57,820,358. Furthermore, Agenus Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. The latest value of Agenus Earnings Before Interest Taxes and Depreciation Amortization EBITDA is -57,820,358.

Another small slide for Agenus

Latest Treynor Ratio is up to 0.08. Price may slide again.
As of the 14th of March 2021, Agenus shows the mean deviation of 3.15, and Risk Adjusted Performance of 0.0303. Agenus Inc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Agenus Inc, which can be compared to its rivals. Please confirm Agenus Inc jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Agenus Inc is priced correctly, providing market reflects its regular price of 3.31 per share. Given that Agenus has jensen alpha of (0.09), we suggest you to validate Agenus Inc's prevailing market performance to make sure the company can sustain itself at a future point.

Our Bottom Line On Agenus Inc

Whereas some other companies in the biotechnology industry are either recovering or due for a correction, Agenus may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Agenus valuation and our trade advice on Agenus is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Agenus.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Agenus Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to